Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise ...

11 August 2026 · By · Wire by Fusion42

Published

11 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

Gilead Sciences has exercised its option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment and potentially enabling up to $1.6 billion in future milestones and royalties related to cancer therapeutics.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now expect increased funding and validation flowing into bispecific cancer therapies from large pharma. Your play in biopharma partnerships just got a clearer path to funding milestones and royalty income.

◆ Coverage

1 source · 11 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiopharmalicensingmilestone-paymentcancer-therapeuticscollaboration